On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL), Prothena Corporation plc (NASDAQ:PRTA), Cumulus Media Inc. (NASDAQ:CMLS), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)
Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL), with shares skyrocketed 32.28%, closed at $1.68.
Prothena Corporation plc (NASDAQ:PRTA), with shares jumped 32.26%, settled at $38.66.
Cumulus Media Inc. (NASDAQ:CMLS), with shares climbed 10.29%, and closed at $2.68.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), surged 4.99%, and closed at $14.31.
Latest NEWS regarding these Stocks are depicted underneath:
Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL)
Formerly on March 16, Hanwha Q CELLS Co., Ltd. (HQCL), one of the world’s largest photovoltaic manufacturer of high-quality, cost-competitive solar modules, declared that its US entity has signed a $20 million three-year Senior Secured Revolving Credit Facility with Wells Fargo Capital Finance. The credit line will be used for working capital and other general corporate purposes.
While on March 9, a top-10 global photovoltaic manufacturer of high-quality, cost-competitive solar modules, has signed a supply contract with juwi solar to supply 75 megawatts (MW) of solar photovoltaic (PV) modules.
“Hanwha Q CELLS is thrilled to be working with juwi,” said Steve Kang, president of Hanwha Q CELLS USA. “We are focused on expanding our utility-scale footprint in the United States, and this deal fits our aims perfectly.”
juwi solar Inc. (JSI) is a solar energy generation corporation based in Boulder, Colorado. JSI’s primary business is the development, design, construction, operation and maintenance of utility-scale (1 MW and larger) solar energy generation facilities in North America.
Hanwha Q CELLS Investment Co., Ltd. manufactures solar cells and modules, solar system solutions, and power plants. The corporation is based in Cayman Islands.
Prothena Corporation plc (NASDAQ:PRTA)
Prothena Corporation plc (PRTA), a late-stage clinical biotechnology corporation focused on the discovery, development and commercialization of novel protein immunotherapy programs, recently declared positive results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson`s disease and other related synucleinopathies. PRX002 is the focus of a worldwide partnership between Prothena and Roche.
PRX002 was safe and well-tolerated, meeting the primary objective of the study. Further, results from this study showed that administration of PRX002 leads to mean reduction of free serum alpha-synuclein levels of up to 96%.
“There is genetic and pathological evidence that supports a causal role of alpha-synuclein in Parkinson`s disease,” said Todd Sherer, PhD, CEO of the Michael J. Fox Foundation for Parkinson`s Research. “We applaud Prothena and Roche for their pioneering work in developing a potentially disease-modifying therapy for this progressive neurodegenerative disease that affects millions worldwide.”
In December 2013, Prothena and Roche reached a worldwide partnership to develop and commercialize antibodies that target alpha-synuclein, counting PRX002. To date, Prothena has received $45 million of the potential $600 million in total milestones through its partnership with Roche. Prothena has an option to co-promote PRX002 in the U.S., where the companies share all profits, in addition to development and commercialization costs, on a 30/70 basis (30% Prothena and 70% Roche). Outside the U.S., Roche will have sole responsibility for developing and commercializing PRX002 and will pay Prothena up to double-digit royalties on net sales.
Prothena Corporation plc is a late-stage clinical biotechnology corporation focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Corporation is developing antibody-based product candidates that target a number of potential indications counting AL amyloidosis (NEOD001), Parkinson`s disease and other related synucleinopathies (PRX002) and psoriasis and other inflammatory diseases (PRX003).
Cumulus Media Inc. (NASDAQ:CMLS)
Cumulus Media Inc. (CMLS), declared that media research, sales and marketing executive Pierre Bouvard has been designated to the newly created role of Chief Marketing Officer. In his new post, Bouvard will lead the marketing strategy for the media and entertainment corporation, counting both its local and national brands. Bouvard will develop targeting applications for advertisers and agencies to reach their ideal audience across Cumulus’ and Westwood One’s 193 million weekly listener footprint. Brand lift and sales measurement will measure influence and optimize future campaigns. He will assume his new role at Cumulus effective March 18, 2015, and will report to Lew Dickey, President and Chief Executive Officer of Cumulus. He will be based in New York City.
Bouvard has over 25 years of experience in media research, purchaser targeting and advertiser ROI measurement in addition to senior leadership roles in sales, marketing and operations, and was formerly Senior Vice President of Sales for TiVo Research & Analytics, Inc. At TiVo Research, he led cross-media targeting and sales lift measurement engagements for Procter & Gamble, Comcast, Turner Broadcasting, and NBCU. As President of Sales for Arbitron Inc., Bouvard led the sales and marketing effort to launch Arbitron’s Portable People Meter (PPM) and he created the out-of-home and custom research divisions. Earlier, Bouvard was Executive Vice President at Coleman Insights, a leading market research and consulting firm to the radio industry in the U.S. and in Europe. At Coleman, he assisted launch the nation’s first Hip Hop formats in Los Angeles and New York City and oversaw the programming and marketing strategies of dozens of successful major market radio stations.
Bouvard said: “Cumulus is America’s fastest growing major radio group. Over the last ten years, their national proceeds have grown tenfold from $50 Million to $500 Million. They have transformed themselves into a major market, cross-media national platform through the merger of Westwood One and Cumulus Radio Networks, the launch of the NASH country music lifestyle brand, and the Rdio online radio partnership. Radio is the soundtrack for the American worker and ‘king of the road’. Cumulus has impressive solutions for advertisers and agencies to reach the right audience and accomplish their brand and sales objectives.”
Bouvard holds a B.S. degree in Communications from Northwestern University. In 2007, he was named by MediaWeek Magazine as one of the 50 most indispensable executives shaping the future of media. He has served on the boards of Adify Inc. and TRA and is presently on the boards of the IRTS, a leading media charity in New York City, and the Library of American Broadcasting.
Cumulus Media Inc. owns and operates radio stations in the United States. It sells commercial advertising time to local, national, and network clients on its radio stations. As the largest pure-play radio broadcaster in the United States, Cumulus provides exclusive content that is fully distributed through about 460 owned-and-operated stations in 90 U.S. media markets (counting eight of the top 10), about 8,500 broadcast radio associates and numerous digital channels.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)
On March 18, Dyadic International, Inc. (DYAI), declared the appointment of Jack Kaye to the Board of Directors, effective April 1, 2015. Mr. Kaye will serve on the audit and compensation committees. With the addition of Mr. Kaye, there will be seven members on the Dyadic Board.
Mr. Kaye is a seasoned financial executive with over forty years of diversified experience. He is presently the Chairman of the Audit Committee of Keryx Biopharmaceuticals, Inc. (KERX), where he has served since 2006. He formerly served on the board of directors of Tongli Pharmaceuticals (USA), Inc., a China-based pharmaceutical corporation and Balboa Biosciences, Inc., a privately held biotech corporation. In addition, he was selected to take part in the Astellas, Inc./OSI. and Roche Pharmaceuticals, Inc./Illumina hostile takeover transactions, and served as a member of the Roche/Illumina dissident board slate. Mr. Kaye began his career at Deloitte LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006. At Deloitte, he was responsible for serving a diverse client base of public and private, global and domestic, companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley issues. In addition, he served as Deloitte’s Tri-State liaison with the banking and finance community and assisted clients with numerous merger and attainment transactions. Preceding to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than twenty years. Mr. Kaye has a Bachelor of Science from Baruch College and is a Certified Public Accountant.
Dyadic International, Inc. is a global biotechnology corporation that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical corporation, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
